Literature DB >> 18836799

Clinical results of N-acetylcysteine after major hepatic surgery: a review.

Andrew McKay1, Darby Cassidy, Francis Sutherland, Elijah Dixon.   

Abstract

BACKGROUND/
PURPOSE: Ischemia/reperfusion injury is thought to play an important role in postoperative liver dysfunction and morbidity following major liver surgery. N-acetylcysteine may be protective by serving as a precursor to glutathione and replenishing intracellular stores, in addition to other mechanisms. The purpose of this review is to summarize the clinical evidence that N-acetylcysteine may reduce liver dysfunction and the postoperative complications following major liver surgery.
METHODS: A PubMed (MEDLINE) search was performed using the search terms "N-acetylcysteine", "Mucomyst", "liver", and "surgery" to identify all relevant articles published in English prior to February 2007.
RESULTS: Seventy-three articles were identified, and of these, there were seven studies that involved human patients undergoing orthotopic liver transplantation (six randomized controlled trials and one retrospective study).
CONCLUSIONS: The evidence that routine use of N-acetylcysteine reduces ischemia/reperfusion injury and prevents complications after major liver surgery is not conclusive. The available studies may have been limited by small sample sizes, and heterogeneous outcome measures prevent conclusions being made across studies and prevent pooling of the data. Further study with more relevant clinical endpoints and larger sample sizes is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836799     DOI: 10.1007/s00534-007-1306-6

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  8 in total

1.  The Effect of Intraoperative N-Acetylcysteine on Hepatocellular Injury During Laparoscopic Bariatric Surgery. A Randomised Controlled Trial.

Authors:  Ajay P Belgaumkar; Kirstin A Carswell; Robin D Hughes; Alberto Quaglia; Anil Dhawan; Ragai R Mitry; Ameet G Patel
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

2.  N-acetylcysteine administration does not improve patient outcome after liver resection.

Authors:  Stuart M Robinson; Rehan Saif; Gourab Sen; Jeremy J French; Bryon C Jaques; Richard M Charnley; Derek M Manas; Steven A White
Journal:  HPB (Oxford)       Date:  2013-01-07       Impact factor: 3.647

3.  Operative terminology and post-operative management approaches applied to hepatic surgery: Trainee perspectives.

Authors:  Shahid G Farid; K Rajendra Prasad; Gareth Morris-Stiff
Journal:  World J Gastrointest Surg       Date:  2013-05-27

4.  Pharmacological Modulation of Ischemic-Reperfusion Injury during Pringle Maneuver in Hepatic Surgery. A Prospective Randomized Pilot Study.

Authors:  Matteo Donadon; Andrea Forastieri Molinari; Francesco Corazzi; Laura Rocchi; Paola Zito; Matteo Cimino; Guido Costa; Ferdinando Raimondi; Guido Torzilli
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

5.  N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells.

Authors:  Rui Wang; James S Malter; Deng-Shun Wang
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Liver transplantation: Advances and perioperative care.

Authors:  Amar Nandhakumar; Stuart A McCluskey; Coimbatore Srinivas; Tony T Chandy
Journal:  Indian J Anaesth       Date:  2012-07

7.  Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc.

Authors:  Martina Haller; Sana Khalid; Leopold Kremser; Friedrich Fresser; Tobias Furlan; Martin Hermann; Julia Guenther; Astrid Drasche; Michael Leitges; Marco Giorgio; Gottfried Baier; Herbert Lindner; Jakob Troppmair
Journal:  J Biol Chem       Date:  2016-09-13       Impact factor: 5.157

8.  d-Pinitol protects against endoplasmic reticulum stress and apoptosis in hepatic ischemia-reperfusion injury via modulation of AFT4-CHOP/GRP78 and caspase-3 signaling pathways.

Authors:  Lei Yan; Heng Luo; Xingsheng Li; Yongyong Li
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.